FDA clears MSD’s Keytruda combo plus Welireg for ccRCC treatment
Pharmaceutical Business Review
This approval covers patients with ccRCC who are at intermediate-high or high risk of recurrence after nephrectomy, or after nephrectomy and resection of metastatic lesions.
pharminent
June 15, 2026 (Last updated: June 15, 2026)
Pharmaceutical Business Review
This approval covers patients with ccRCC who are at intermediate-high or high risk of recurrence after nephrectomy, or after nephrectomy and resection of metastatic lesions.